STOCK TITAN

Neurocrine Biosciences Inc - $NBIX STOCK NEWS

Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: $NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neurocrine Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neurocrine Biosciences's position in the market.

Rhea-AI Summary
Neurocrine Biosciences, Inc. (NBIX) announced a 26% year-over-year growth in INGREZZA® (valbenazine) net product sales for the second quarter, reaching $440 million. The company also raised 2023 net product sales guidance to $1.77 - $1.82 billion, reflecting the significant benefit the medicine provides to patients with tardive dyskinesia. The financial results revealed a record number of new patients receiving therapy, with GAAP net income and earnings per share of $96 million and $0.95, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
-
Rhea-AI Summary
Neurocrine Biosciences has appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors. Ms. Poon has a 30-year career in the healthcare industry, including serving as Vice Chairman and Member of the Board of Directors of Johnson & Johnson. She brings a wealth of industry experience to Neurocrine's Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
management
-
Rhea-AI Summary
Neurocrine Biosciences, Inc. has scheduled its second quarter 2023 financial results conference call and webcast for August 1, 2023 at 5:00 a.m. PT / 8:00 a.m. ET. The press release will be issued at 4:00 a.m. PT / 7:00 a.m. ET. Investors can access the webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences
-
Rhea-AI Summary
Neurocrine Biosciences announces positive results from Phase 3 study of valbenazine for the treatment of chorea associated with Huntington's disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
Neurocrine Biosciences Inc

Nasdaq:NBIX

NBIX Rankings

NBIX Stock Data

14.16B
98.22M
1%
94.39%
2.44%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About NBIX

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders